NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis $4.45 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$4.53 +0.08 (+1.69%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arbutus Biopharma Stock (NASDAQ:ABUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arbutus Biopharma alerts:Sign Up Key Stats Today's Range$4.38▼$4.6850-Day Range$4.29▼$5.2152-Week Range$3.50▼$5.45Volume8.99 million shsAverage Volume7.82 million shsMarket Capitalization$881.59 millionP/E Ratio5.63Dividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company Overview Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection and other viral diseases. The company’s research programs are based primarily on RNA interference (RNAi) therapeutics and small-molecule compounds designed to suppress viral replication and address the underlying biology of persistent infection. Arbutus’ HBV pipeline has included AB-729, an investigational subcutaneously administered RNAi therapeutic intended to reduce hepatitis B surface antigen, and AB-836, an investigational oral capsid inhibitor designed to interfere with HBV replication. The company also develops and licenses lipid nanoparticle delivery technology, which is intended to help transport nucleic acid medicines into cells. The company traces its history to Tekmira Pharmaceuticals, which combined with OnCore Biopharma in 2015 and adopted the Arbutus Biopharma name. Arbutus is headquartered in Warminster, Pennsylvania, and conducts research and clinical development through collaborations and studies involving international markets. Its leadership and development strategy have centered on advancing targeted therapies for chronic viral infections while leveraging its expertise in RNA medicines and drug-delivery technologies.AI Generated. May Contain Errors. Read More Arbutus Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreABUS MarketRank™: Arbutus Biopharma scored higher than 43% of companies evaluated by MarketBeat, and ranked 590th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingArbutus Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialArbutus Biopharma has a consensus price target of $5.00, representing about 12.4% upside from its current price of $4.45.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is 5.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.66.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is 5.63, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.01.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 11.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arbutus Biopharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.65% of the float of Arbutus Biopharma has been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 5.01.Change versus previous monthShort interest in Arbutus Biopharma has recently decreased by 2.28%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.71 News SentimentArbutus Biopharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows3 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders19.90% of the stock of Arbutus Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABUS Stock News HeadlinesArbutus Announces Final Results of Its US$230 Million Modified 'Dutch Auction' Tender OfferOctober 2 at 7:50 AM | marketscreener.comMTranche Update on Arbutus Biopharma Corporation's Equity Buyback Plan announced on August 21, 2026.October 1, 2026 | marketscreener.comMTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 5 at 1:00 AM | Porter & Company (Ad)Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender OfferOctober 1, 2026 | financialpost.comFArbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender OfferOctober 1, 2026 | globenewswire.comArbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender OfferSeptember 30, 2026 | financialpost.comFArbutus Biopharma Announces Preliminary Results of US$230 Million Substantial Issuer Bid Tender OfferSeptember 30, 2026 | quiverquant.comQArbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender OfferSeptember 30, 2026 | globenewswire.comSee More Headlines ABUS Stock Analysis - Frequently Asked Questions How have ABUS shares performed this year? Arbutus Biopharma's stock was trading at $4.81 at the beginning of 2026. Since then, ABUS stock has decreased by 7.5% and is now trading at $4.45. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Corporation (NASDAQ:ABUS) announced its quarterly earnings data on Thursday, August, 13th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.01. The biopharmaceutical company had revenue of $1.01 million for the quarter, compared to the consensus estimate of $0.70 million. Arbutus Biopharma had a trailing twelve-month return on equity of 90.98% and a net margin of 84.22%. Is Arbutus Biopharma buying back stock? Arbutus Biopharma's Board of Directors authorized a share buyback plan on Friday, August 21st 2026, which allows the company to repurchase $0 in shares, according to EventVestor. This allows the company to repurchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its shares are undervalued. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Bausch Health Cos (BHC), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and NVIDIA (NVDA). Company Calendar Last Earnings8/13/2026Today10/05/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ABUS's financial health is in the Green zone, according to TradeSmith. ABUS has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABUS CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees19Year Founded2005Price Target and Rating Average Price Target for Arbutus Biopharma$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+12.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.79 Trailing P/E Ratio5.63 Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.50 million Net Margins84.22% Pretax Margin84.22% Return on Equity90.98% Return on Assets82.34% Debt Debt-to-Equity RatioN/A Current Ratio81.42 Quick Ratio81.42 Sales & Book Value Annual Sales$14.08 million Price / Sales62.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book11.13Miscellaneous Outstanding Shares198,110,000Free Float158,683,000Market Cap$881.59 million OptionableOptionable Beta0.76 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ABUS) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
